

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****Government-Owned Inventions; Availability for Licensing**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development.

**FOR FURTHER INFORMATION CONTACT:**

Licensing information and copies of the U.S. patent application listed below may be obtained by communicating with Sury Vepa, Ph.D., J.D., Senior Licensing and Patenting Manager, National Center for Advancing Translational Sciences, NIH, 9800 Medical Center Drive, Rockville, MD 20850, Phone: 301-827-7181, or email [sury.vepa@nih.gov](mailto:sury.vepa@nih.gov). A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.

**SUPPLEMENTARY INFORMATION:**

Technology description follows.

**Inhibitors of Phosphoinositide 3-Kinase and Histone Deacetylase for Treatment of Cancer**

*Description of Technology:* The invention includes compounds that act as dual inhibitor of phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC), including a core containing a quinazoline moiety or a quinazolin-4(3H)-one moiety, a kinase hinge binding moiety, and a histone deacetylase pharmacophore, a pharmaceutically acceptable salt thereof, a prodrug thereof, or solvate thereof. The present invention also provides compounds that are selective inhibitors of histone deacetylase inhibitor that include a core containing a quinazolin-4(3H)-one moiety and a histone deacetylase pharmacophore.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

*Potential Commercial Applications:*

- Novel therapeutics for cancers neurodegenerative diseases.
- *Competitive Advantages:*
  - Novel dual inhibitor compounds of this invention have a commercial advantage over those currently known

because they can act as selective and dual inhibitors of specific isoforms of HDAC (such as HDAC6) and PI3K (such as PI3K $\delta$ ) potentially providing better toxicity profile and therefore bigger therapeutic window.

*Development Stage:*

- Pre-Clinical (compound optimization and in vivo validation).

*Inventors:*

- Grewal, Gurmit; Thakur, Ashish; Tawa, Gregory James; Ferrer, Marc; and Simeonov, Anton M.

*Intellectual Property:* 1. INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND HISTONE DEACETYLASE FOR TREATMENT OF CANCER, PCT Patent Application NO. PCT/US2018/038507 filed on June 20, 2018 (HHS Ref. No. E-104-2017).

*Licensing Contact:* Sury Vepa, Ph.D., J.D. Phone: 301-827-7181, or email [sury.vepa@nih.gov](mailto:sury.vepa@nih.gov).

Dated: October 1, 2019.

**Lillianne M. Portilla Weingarten,**

*Technology Development Coordinator, National Center for Advancing Translational Sciences.*

[FR Doc. 2019-21965 Filed 10-7-19; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****National Center for Advancing Translational Sciences; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Center for Advancing Translational Sciences Special Emphasis Panel; Drug Screening with Bio Fabricated 3-D Skin Disease Tissue Models.

*Date:* October 23, 2019.

*Time:* 2:00 p.m. to 5:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Rahat (Rani) Khan, Ph.D., Scientific Review Officer, Office of Scientific Review, National Center for Advancing Translational Sciences, 6701 Democracy Blvd., Rm 1078, Bethesda, MD 20892, 301-894-7319, [khanr2@csr.nih.gov](mailto:khanr2@csr.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: October 2, 2019.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2019-21851 Filed 10-7-19; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****Eunice Kennedy Shriver National Institute of Child Health & Human Development; Amended Notice of Meeting**

Notice is hereby given of a change in the meeting of the National Institute of Child Health and Human Development Special Emphasis Panel on Pediatric Trauma and Injury Prevention, which was published in the **Federal Register** on September 25, 2019, 84 FR 50460.

This meeting's location and format has changed from an in-person meeting at the Residence Inn, Bethesda MD to an IAT/Teleconference meeting at 6710B Rockledge Dr., Bethesda MD. The meeting is closed to the public.

Dated: October 2, 2019.

**Ronald J. Livingston, Jr.,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2019-21850 Filed 10-7-19; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****Center for Scientific Review; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial